1. Home
  2. PRAX vs KNX Comparison

PRAX vs KNX Comparison

Compare PRAX & KNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

N/A

Current Price

$302.98

Market Cap

9.6B

Sector

Health Care

ML Signal

N/A

Logo Knight-Swift Transportation Holdings Inc.

KNX

Knight-Swift Transportation Holdings Inc.

N/A

Current Price

$52.02

Market Cap

7.0B

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
PRAX
KNX
Founded
2015
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Trucking Freight/Courier Services
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
9.6B
7.0B
IPO Year
2020
2010

Fundamental Metrics

Financial Performance
Metric
PRAX
KNX
Price
$302.98
$52.02
Analyst Decision
Strong Buy
Buy
Analyst Count
15
18
Target Price
$572.13
$60.50
AVG Volume (30 Days)
325.2K
2.6M
Earning Date
05-12-2026
04-21-2026
Dividend Yield
N/A
1.29%
EPS Growth
N/A
N/A
EPS
N/A
0.41
Revenue
N/A
$7,469,689,000.00
Revenue This Year
N/A
$5.92
Revenue Next Year
$6,395.88
$7.91
P/E Ratio
N/A
$135.80
Revenue Growth
N/A
0.80
52 Week Low
$26.70
$36.69
52 Week High
$354.87
$64.10

Technical Indicators

Market Signals
Indicator
PRAX
KNX
Relative Strength Index (RSI) 42.73 34.17
Support Level $290.36 $41.21
Resistance Level $322.32 $54.03
Average True Range (ATR) 16.79 2.52
MACD -4.88 -1.04
Stochastic Oscillator 25.06 0.17

Price Performance

Historical Comparison
PRAX
KNX

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

About KNX Knight-Swift Transportation Holdings Inc.

Knight-Swift is the largest full-truckload carrier in the US, with a diversified transportation offering. Pro forma for the US Xpress deal, about 82% of revenue derives from Knight's asset-based trucking business, with full truckload (for-hire dry van, refrigerated, and dedicated contract) making up 69% and less than truckload 13%. Truck brokerage and other asset-light logistics services make up 9% of revenue, with intermodal near 6%. Knight's intermodal operations use the Class I railroads for the underlying movement of its shipping containers and include drayage (regional trucking services to and from inland intermodal ramps/terminals). The remainder of revenue reflects services offered to shippers and third-party truckers, including equipment maintenance and leasing.

Share on Social Networks: